Knotus Co Ltd
KOSDAQ:278650
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 995
4 510
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Knotus Co Ltd
Note Receivable
Knotus Co Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Note Receivable
₩970m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Note Receivable
₩287B
|
CAGR 3-Years
15%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Note Receivable
₩2.6B
|
CAGR 3-Years
72%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Note Receivable
₩98.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Note Receivable
₩1.9k
|
CAGR 3-Years
-98%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Knotus Co Ltd
Glance View
KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.
See Also
What is Knotus Co Ltd's Note Receivable?
Note Receivable
970m
KRW
Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Note Receivable amounts to 970m KRW.
What is Knotus Co Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
-10%
Over the last year, the Note Receivable growth was 4 750%. The average annual Note Receivable growth rates for Knotus Co Ltd have been 6% over the past three years , -10% over the past five years .
You don't have any saved screeners yet
